MX2023010183A - Polipeptidos variantes de actinohivina y metodos relacionados. - Google Patents
Polipeptidos variantes de actinohivina y metodos relacionados.Info
- Publication number
- MX2023010183A MX2023010183A MX2023010183A MX2023010183A MX2023010183A MX 2023010183 A MX2023010183 A MX 2023010183A MX 2023010183 A MX2023010183 A MX 2023010183A MX 2023010183 A MX2023010183 A MX 2023010183A MX 2023010183 A MX2023010183 A MX 2023010183A
- Authority
- MX
- Mexico
- Prior art keywords
- actinohivin
- related methods
- variant polypeptides
- cancer cells
- polypeptides
- Prior art date
Links
- 101710109084 Actinohivin Proteins 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 abstract 2
- 206010033128 Ovarian cancer Diseases 0.000 abstract 2
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163156715P | 2021-03-04 | 2021-03-04 | |
| PCT/US2022/070961 WO2022187851A1 (en) | 2021-03-04 | 2022-03-04 | Actinohivin variant polypeptides and related methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023010183A true MX2023010183A (es) | 2023-11-22 |
Family
ID=83155364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010183A MX2023010183A (es) | 2021-03-04 | 2022-03-04 | Polipeptidos variantes de actinohivina y metodos relacionados. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240123026A1 (enExample) |
| EP (1) | EP4301389A4 (enExample) |
| JP (1) | JP2024509385A (enExample) |
| CN (1) | CN117098545A (enExample) |
| AU (1) | AU2022229597A1 (enExample) |
| CA (1) | CA3210629A1 (enExample) |
| IL (1) | IL305259A (enExample) |
| MX (1) | MX2023010183A (enExample) |
| WO (1) | WO2022187851A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018148541A1 (en) | 2017-02-10 | 2018-08-16 | University Of Louisville Research Foundation, Inc. | Actinohivin variant polypeptides and related methods |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012071492A1 (en) * | 2010-11-23 | 2012-05-31 | Georgia Tech Research Corporation | Mir-200 family induces mesenchymal-to-epithelial transition (met) in ovarian cancer cells |
| EP3194973A1 (en) * | 2014-09-17 | 2017-07-26 | Institut Curie | Map3k8 as a marker for selecting a patient affected with an ovarian cancer for a treatment with a mek inhibitor |
| WO2018148541A1 (en) * | 2017-02-10 | 2018-08-16 | University Of Louisville Research Foundation, Inc. | Actinohivin variant polypeptides and related methods |
-
2022
- 2022-03-04 JP JP2023550178A patent/JP2024509385A/ja active Pending
- 2022-03-04 IL IL305259A patent/IL305259A/en unknown
- 2022-03-04 WO PCT/US2022/070961 patent/WO2022187851A1/en not_active Ceased
- 2022-03-04 CN CN202280015649.3A patent/CN117098545A/zh active Pending
- 2022-03-04 CA CA3210629A patent/CA3210629A1/en active Pending
- 2022-03-04 EP EP22764272.5A patent/EP4301389A4/en active Pending
- 2022-03-04 MX MX2023010183A patent/MX2023010183A/es unknown
- 2022-03-04 US US18/277,684 patent/US20240123026A1/en active Pending
- 2022-03-04 AU AU2022229597A patent/AU2022229597A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117098545A (zh) | 2023-11-21 |
| IL305259A (en) | 2023-10-01 |
| CA3210629A1 (en) | 2022-09-09 |
| WO2022187851A1 (en) | 2022-09-09 |
| AU2022229597A1 (en) | 2023-10-19 |
| US20240123026A1 (en) | 2024-04-18 |
| JP2024509385A (ja) | 2024-03-01 |
| EP4301389A4 (en) | 2025-03-12 |
| EP4301389A1 (en) | 2024-01-10 |
| WO2022187851A9 (en) | 2022-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021009259A (es) | Conjugados de il-2 y metodos de uso del mismo. | |
| CY1126855T1 (el) | Ενωσεις κυκλικων δινουκλεοτιδιων για τη θεραπευτικη αγωγη καρκινου | |
| CL2019002368A1 (es) | Composiciones y métodos para el tratamiento de cáncer. | |
| MX2021007620A (es) | Inmunoconjugados de anticuerpos receptor huerfano similar al receptor tirosina cinasa 1 (ror1). | |
| CL2024001473A1 (es) | Conjugados de fármacos y anticuerpos anti-ccr7 | |
| CL2019002478A1 (es) | Formulación de anticuerpo monoclonal anti-vrs. | |
| MX2019010282A (es) | Formulacion de anticuerpos monoclonales. | |
| MX2020009757A (es) | Producto combinado de inhibidor de bcl-2 e inhibidor de mdm2 y uso de este en la prevencion y/o tratamiento de enfermedades. | |
| CL2023003965A1 (es) | Inhibidores cdk2. | |
| MX2019000216A (es) | Compuestos, composiciones y metodos para el tratamiento de enfermedades. | |
| MX2020013320A (es) | Inhibidores de ectonucleotidasa y métodos de uso de los mismos. | |
| CO2022009737A2 (es) | Anticuerpos anti-ly6g6d y métodos de uso | |
| CO2021009129A2 (es) | Tubulisinas y conjugados de proteína-tubulisina | |
| SA519410840B1 (ar) | إثارة باستشعاع الطاقة الضوئية | |
| TWD191630S (zh) | Reaction tube | |
| DOP2021000113A (es) | Anticuerpos antiperiostina y usos de estos | |
| CL2025000366A1 (es) | Composiciones y metodos para el tratamiento de presicion del cancer | |
| MX2019000235A (es) | Eliminacion de la cistina mediada por enzimas humanas. | |
| MX2018013484A (es) | Nuevos anticuerpos anti-tnfrsf21 y modos de uso. | |
| MX2022014254A (es) | Anticuerpos anti-hemojuvelina (hjv) para tratar mielofibrosis. | |
| WO2020033019A3 (en) | Novel mct4 inhibitors and uses thereof | |
| CL2023002812A1 (es) | Combinaciones farmacéuticas para el tratamiento del cáncer | |
| CU20190019A7 (es) | Combinaciones que incluyen abx196 útiles en el tratamiento del cáncer | |
| CL2021003442A1 (es) | Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer. | |
| UY38319A (es) | Composición farmacéutica para el tratamiento de la adicción a sustancias psicoactivas y/o para la prevención de las recaídas a dicha adicción |